Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + paclitaxel + cisplatin + bevacizumab
- Development stage
- Phase 2
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**iparomlimab + tuvonralimab + paclitaxel + cisplatin + bevacizumab** is an investigational combination regimen being evaluated for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. The regimen consists of iparomlimab and tuvonralimab (QL1706), a first-in-class bifunctional MabPair product containing a mixture of anti-PD-1 (iparomlimab) and anti-CTLA-4 (tuvonralimab) monoclonal antibodies co-produced from a single cell line; paclitaxel, a microtubule-stabilizing taxane chemotherapy; cisplatin, a platinum-based alkylating chemotherapy (with carboplatin as an alternative); and bevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF) to inhibit angiogenesis. In the Phase III QL1706-301 trial (NCT05446883), the addition of QL1706 to standard chemotherapy (paclitaxel + cisplatin/carboplatin) with or without bevacizumab demonstrated a significant improvement in progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer.
- Other names
- PSB205 + paclitaxel + cisplatin + bevacizumabQL1706 + paclitaxel + cisplatin + AvastinQL1706 + paclitaxel + cisplatin + bevacizumabiparomlimab + tuvonralimab + paclitaxel + cisplatin + bevacizumabiparomlimab and tuvonralimab + paclitaxel + cisplatin + bevacizumabiparomlimab/tuvonralimab + paclitaxel + cisplatin + bevacizumab
02
Targets
CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + paclitaxel + cisplatin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + paclitaxel + cisplatin + bevacizumab.